LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...
For classical hematologist Srila Gopal, MD, overseeing the care of about 250 adults with sickle cell disease (SCD) and thalassemia isn’t just a matter of diagnosis and treatment. In just a single week ...
81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...
Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...
The Department of Health and Human Services (HHS), Office of Minority Health requests that the National Academies of Sciences, Engineering, and Medicine convene an ad hoc committee to develop a ...
Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...
India accounts for the second-highest prevalence of sickle cell disease (SCD) globally, following sub-Saharan Africa. However, not much research has been done, and no stigma measurement tool was ...
Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026. In a presentation set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback